Endogenous Catecholamines in Immune Cells: Discovery, Functions And Clinical Potential as Therapeutic Targets
The IL-6 Inhibitors Tocilizumab and Sarilumab and COVID-19 Treatment: Controversies but Potential Efficacy in Severe Cases
Donna Jackson Nakazawa and Her New Book, THE ANGEL AND THE ASSASSIN: The Tiny Brain Cell that Changed the Course of Medicine
Encouraging Results from Phase 2a COVID-19 Clinical Trial with the Oral Direct-Acting Antiviral MolnupiravirJuly 7, 2021
New evidence linking platelet-activating anti-PF4 antibodies to the vaccine-induced immune thrombotic thrombocytopeniaApril 19, 2021
Identification of GM-SCF as possible distinctive blood marker predicting severe COVID-19March 23, 2021
Monogenic immune defects in type I interferon pathways as a risk factor for severe COVID-19 pneumoniaJanuary 29, 2021
FDA Authorizes an Emergency Use for Bamlanivimab – an Investigational Monoclonal Antibody – for the Treatment of Mild to Moderate COVID-19November 11, 2020
High Affinity Human Antibody Component Identified as a Potential Targeted SARS-Cov-2 TherapyNovember 3, 2020
NIH begins the first large randomized controlled trial of the combination of interferon beta-1a and remdesivir for treating COVID-19August 13, 2020
The European Commission Approves Remdesivir for the Treatment of Severe Cases of COVID-19July 4, 2020
First Evidence that the Antiviral Remdesivir Shows Efficacy in an Animal Model (Rhesus Macaques) of COVID-19April 24, 2020
Favipiravir (Avigan) Shows Therapeutic Efficacy in Treating Coronavirus in Two Clinical Trials Conducted in ChinaMarch 19, 2020
